Edwards Lifesciences
EW
$86.07
-0.98%
Edwards Lifesciences is a global leader in structural heart disease medical devices, specializing in surgical tissue heart valves, transcatheter aortic valve replacement (TAVR) systems, and transcatheter mitral and tricuspid therapies. Spun off from Baxter in 2000, the company holds a dominant position in the TAVR market, with about 60% of sales outside the U.S. The current investor narrative centers on a proposed Medicare expansion for TAVR procedures, which could significantly broaden the addressable market, and the company's recent beat-and-raise quarter demonstrating robust demand for its heart valve innovations.…
EW
Edwards Lifesciences
$86.07
Related headlines
EW 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Edwards Lifesciences's 12-month outlook, with a consensus price target around $100.96 and implied upside of +17.3% versus the current price.
Average Target
$100.96
0 analysts
Implied Upside
+17.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$84 - $110
Analyst target range
Edwards Lifesciences is covered by 25 analysts, with a consensus recommendation of 'Buy' (mean rating 1.74 on a 1-5 scale). The average target price is $100.36, implying 21.5% upside from the current price of $82.63. The distribution leans bullish, with no sell ratings and a majority of buy/outperform ratings. Recent ratings from Mizuho, RBC Capital, and Citigroup reaffirm positive outlooks. The target price range spans from $84.00 (low) to $110.00 (high), indicating a 31% spread between the most bearish and bullish views. The high target of $110 assumes successful TAVR expansion and margin improvement, while the low target of $84 suggests limited upside if growth disappoints. The wide spread reflects uncertainty around regulatory catalysts and competitive dynamics. Recent analyst actions have been stable, with no downgrades, signaling conviction in the company's growth trajectory.
Drowning in data?
Find the real signal!
Bulls vs Bears: EW Investment Factors
Edwards Lifesciences presents a compelling growth story with accelerating revenue, expanding margins, and a strong balance sheet, supported by a potential Medicare expansion catalyst. The bull case is anchored by 16.7% revenue growth, 31.2% operating margins, and 21.5% upside to the average analyst target. However, the bear case highlights an elevated trailing P/E of 46.33x, recent price weakness with 7.84% monthly decline, and competitive/regulatory uncertainties. The single most important tension is whether the company can sustain its growth trajectory and margin expansion to justify the forward P/E of 24.58x. Currently, the bull case has stronger evidence given the accelerating fundamentals and favorable regulatory catalyst, but the stock's recent underperformance warrants caution. The key factor to watch is the resolution of the Medicare coverage expansion, which could drive a significant re-rating.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 16.7% YoY to $1.649B, accelerating from 15.3% in Q4 2025 and 13.5% in Q3 2025, driven by strong TAVR adoption and new product launches.
- Expanding Profit Margins: Operating margin improved to 31.2% in Q1 2026 from 23.6% in Q4 2025, reflecting operating leverage. Net margin of 23.1% is well above industry averages for medical devices.
- Fortress Balance Sheet: Debt-to-equity ratio is just 0.068 and current ratio is 3.72, indicating minimal leverage and strong liquidity. Free cash flow TTM is $1.09B, funding growth without external capital.
- Medicare Expansion Catalyst: A proposed Medicare expansion for TAVR procedures could significantly broaden the addressable market. Edwards is the market leader, poised to benefit disproportionately from increased procedure volumes.
Bearish
- Elevated Trailing P/E Multiple: Trailing P/E of 46.33x is high relative to the broader market and medical device peers, leaving little room for error. The forward P/E of 24.58x implies aggressive earnings growth expectations.
- Recent Price Weakness: The stock has declined 7.84% over the past month and 1.81% over three months, underperforming the S&P 500 by 8.62% and 5.31% respectively. This suggests near-term selling pressure or rotation out of healthcare.
- Competitive and Regulatory Risks: TAVR market faces competition from Medtronic and Boston Scientific. Any adverse regulatory changes or reimbursement cuts could pressure margins. The wide analyst target spread ($84-$110) reflects uncertainty.
- Negative Free Cash Flow in Q1: Despite strong TTM FCF of $1.09B, Q1 2026 saw negative FCF of -$21.1M due to working capital changes. If this persists, it could signal operational inefficiencies or rising capital needs.
EW Technical Analysis
Edwards Lifesciences is in a range-bound consolidation phase after a strong recovery from its 52-week low of $72.30. Over the past year, the stock has gained 9.01%, but it currently trades at $82.63, which is 85.8% of its 52-week range ($72.30-$96.29). This positioning near the midpoint suggests a lack of clear directional conviction, as the stock has failed to break out to new highs but also avoided a breakdown to lows. The 1-year return underperforms the S&P 500's 16.47% gain, indicating relative weakness in the healthcare sector. Short-term momentum is negative, with the stock declining 7.84% over the past month and 1.81% over the past three months. This recent weakness contrasts with the positive 1-year trend, signaling a potential pullback or consolidation within the broader uptrend. The 1-month relative strength versus the S&P 500 is -8.62%, confirming underperformance. The 52-week high of $96.29 acts as key resistance, while the 52-week low of $72.30 provides support. A breakout above $96.29 would signal a resumption of the uptrend, while a breakdown below $72.30 could indicate further downside. The stock's beta is not provided, but its 1-year volatility relative to the market suggests moderate risk; the 1-year relative strength of -7.46% implies the stock has been less volatile than the S&P 500 on the downside.
Beta
0.85
0.85x market volatility
Max Drawdown
-13.2%
Largest decline past year
52-Week Range
$72-$96
Price range past year
Annual Return
+8.5%
Cumulative gain past year
| Period | EW Return | S&P 500 |
|---|---|---|
| 1m | -6.4% | +0.2% |
| 3m | +2.5% | +3.7% |
| 6m | +5.8% | +8.0% |
| 1y | +8.5% | +18.2% |
| ytd | +0.9% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EW Fundamental Analysis
Edwards Lifesciences reported Q1 2026 revenue of $1.649 billion, a 16.7% year-over-year increase, accelerating from the 15.3% growth in Q4 2025 and 13.5% in Q3 2025. The growth is driven by its Transcatheter Heart Valves segment ($1.197 billion) and Transcatheter Mitral and Tricuspid Therapies ($175 million). The revenue trajectory is strong and accelerating, supported by expanding TAVR adoption and new product launches. The company is highly profitable, with Q1 2026 net income of $380.7 million and a net margin of 23.1%. Gross margin remains robust at 78.2%, while operating margin improved to 31.2% in Q1 2026 from 23.6% in Q4 2025, reflecting operating leverage. Margins are expanding, and the company's profitability is well above industry averages for medical devices. Edwards has a fortress balance sheet with a debt-to-equity ratio of just 0.068 and a current ratio of 3.72. Free cash flow for the trailing twelve months is $1.09 billion, though Q1 2026 saw negative FCF of -$21.1 million due to working capital changes. Return on equity is 10.4%, indicating efficient capital use. The company generates ample cash to fund operations and growth without relying on external financing.
Quarterly Revenue
$1.6B
2026-03
Revenue YoY Growth
+16.7%
YoY Comparison
Gross Margin
78.2%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EW Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 46.33x, while the forward P/E is 24.58x, implying the market expects significant earnings growth. The gap between trailing and forward P/E suggests that earnings are expected to nearly double, reflecting optimism about margin expansion and revenue growth. Compared to the industry average (not provided), Edwards' P/E of 46.33x appears elevated, but the forward P/E of 24.58x is more reasonable. The PEG ratio is -0.63, which is negative due to negative earnings growth expectations (likely a data anomaly), but the forward P/E suggests a growth premium. Historically, Edwards' trailing P/E has ranged from 28.5x (Q4 2024) to 133.2x (Q4 2025), with the current 46.33x near the lower end of the recent range. This suggests the stock is not overvalued relative to its own history, but the low P/E in Q4 2025 was due to depressed earnings. The current valuation implies the market expects a recovery in earnings, which is supported by the strong Q1 2026 results.
PE
46.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 27x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Edwards Lifesciences carries a trailing P/E of 46.33x, which is elevated and implies high growth expectations. Any earnings miss could lead to multiple compression. While the balance sheet is strong with a debt-to-equity ratio of 0.068, the negative free cash flow of -$21.1M in Q1 2026 is a minor concern, though TTM FCF remains robust at $1.09B. The company's profitability is high (net margin 23.1%), but reliance on continued margin expansion to justify the forward P/E of 24.58x introduces risk if input costs rise or pricing pressure emerges. Revenue concentration in TAVR (about 73% of total revenue) makes the company vulnerable to any disruption in that market.
Market & Competitive Risks: The stock has underperformed the S&P 500 by 7.46% over the past year, indicating relative weakness. With a beta not provided, the stock's correlation to market movements is unclear, but the 1-year relative strength of -7.46% suggests it has been less volatile on the downside. Competitive threats from Medtronic and Boston Scientific in the TAVR space could erode market share. Regulatory risk is significant: any adverse changes to Medicare coverage or reimbursement for TAVR could dampen growth. The wide analyst target range ($84-$110) reflects uncertainty around these factors. Recent news about a proposed Medicare expansion is a positive catalyst, but if it fails to materialize, the stock could suffer.
Worst-Case Scenario: In a severe adverse scenario, if the Medicare expansion is delayed or denied, and competition intensifies, revenue growth could decelerate sharply. Earnings could miss expectations, leading to multiple compression. The stock could fall to its 52-week low of $72.30, representing a 12.5% decline from the current price of $82.63. In a more extreme case, if the company faces a product recall or regulatory setback, the stock could drop further, potentially testing the $70 level. The historical max drawdown of -13.19% suggests a realistic downside of about 13% from current levels, implying a target of $71.80. Investors could lose up to 12-15% in a worst-case scenario.
